BeOne registers pediatric trial of sonrotoclax in relapsed AML and B-cell ALL

BeOne Medicines had one registry update during the week.

• "A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia" (NCT07770698) is a Phase 1/2a, open-label trial sponsored by BeOne Medicines, listed as not yet recruiting with an estimated enrollment of 30 participants. The study will investigate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sonrotoclax in combination with other agents in pediatric patients aged 6 months to 17 years with relapsed or refractory acute myeloid leukemia and B-cell acute lymphoblastic leukemia.¹ One cohort pairs sonrotoclax with azacitidine in participants with relapsed or refractory acute myeloid leukemia¹, while a second cohort combines sonrotoclax with inotuzumab ozogamicin and dexamethasone in participants with relapsed or refractory B-cell acute lymphoblastic leukemia¹. Estimated start is December 2026, with primary completion estimated for April 30, 2030.